What Trinity Biotech Plc does.

We are a biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. Following the acquisition of the biosensor assets of Waveform Technologies Inc. (“Waveform”) in 2024, we have been developing a range of biosensor devices and related services, beginning with a continuous glucose monitoring (“CGM”) product. Through our subsidiaries, we develop, acquire, manufacture and market medical diagnostic products for the clinical laboratory and point‑of‑care segments of the diagnostic market. Our products are used to detect autoimmune, infectious and sexually transmitted diseases, disorders of the liver and intestine, and to monitor markers for diabetes. We market our portfolio of several hundred products to customers in approximately 100 countries around the world through our own sales force and a network of international distributors and strategic partners.

While our executive offices are located at Bray, Ireland, our research and development, manufacturing and marketing activities are principally conducted by the following subsidiaries:

We sell our products through our direct sales organisations in the United States, Brazil and to an extent in the United Kingdom, France and Germany and then through our network of principal distributors and non-governmental bodies into approximately 100 countries globally.

Revenue and profit, by fiscal year.

More on TRIB.

• Trinity Biotech Plc summary
• Trinity Biotech Plc financial statements
• Trinity Biotech Plc key metrics
• Trinity Biotech Plc health scores and style box
• Trinity Biotech Plc earnings
• Trinity Biotech Plc dividends
• Trinity Biotech Plc valuation
• Trinity Biotech Plc ownership and insiders
• Trinity Biotech Plc peers

Figures from Trinity Biotech Plc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.